Biocon rose 1.94% to Rs 392.45 after its wholly owned subsidiary, Biocon Biologics, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Market Samachar is a news aggregator. This article was originally published by Share Market Today. Tap the button above to read the full story on their site.